BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 121 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2018. The put-call ratio across all filers is 0.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $640,000 | +45.8% | 4,392 | +18.6% | 0.01% | +100.0% |
Q1 2022 | $439,000 | +23.3% | 3,702 | +38.1% | 0.00% | 0.0% |
Q4 2021 | $356,000 | +23.6% | 2,681 | +29.5% | 0.00% | +50.0% |
Q3 2021 | $288,000 | +43.3% | 2,070 | 0.0% | 0.00% | +100.0% |
Q2 2021 | $201,000 | +42.6% | 2,070 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $141,000 | -20.3% | 2,070 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $177,000 | +50.0% | 2,070 | +13.7% | 0.00% | 0.0% |
Q3 2020 | $118,000 | +202.6% | 1,820 | +237.0% | 0.00% | – |
Q2 2020 | $39,000 | +8.3% | 540 | -49.1% | 0.00% | – |
Q1 2020 | $36,000 | -50.7% | 1,060 | -21.2% | 0.00% | -100.0% |
Q4 2019 | $73,000 | +58.7% | 1,345 | +22.3% | 0.00% | – |
Q3 2019 | $46,000 | +475.0% | 1,100 | +511.1% | 0.00% | – |
Q2 2019 | $8,000 | -11.1% | 180 | 0.0% | 0.00% | – |
Q1 2019 | $9,000 | +28.6% | 180 | 0.0% | 0.00% | – |
Q4 2018 | $7,000 | 0.0% | 180 | 0.0% | 0.00% | – |
Q3 2018 | $7,000 | – | 180 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 1,111,111 | $154,344,000 | 72.03% |
Knoll Capital Management, LLC | 856,844 | $119,024,000 | 59.36% |
ORACLE INVESTMENT MANAGEMENT INC | 2,124,055 | $295,053,000 | 36.73% |
ARS Investment Partners, LLC | 466,668 | $64,825,000 | 6.49% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 365,373 | $50,754,000 | 6.18% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $24,490,000 | 5.91% |
SILVERARC CAPITAL MANAGEMENT, LLC | 61,897 | $8,598,000 | 4.86% |
DAFNA Capital Management LLC | 88,100 | $12,238,000 | 3.25% |
Avidity Partners Management LP | 934,200 | $129,770,000 | 2.88% |
Eventide Asset Management | 1,325,000 | $184,056,000 | 2.43% |